Skip to content
Regulatory notice

HospitalsAescia for Hospitals is an investigational Software as a Medical Device under the TGA Class IIa pathway. Not yet available for commercial supply.

ClinicsAescia for Clinics is a workflow and patient-preparation tool. It does not propose clinical decisions and is not a medical device.

Team

Clinicians building for clinicians.

Aescia is built by a small team that writes its own pathways and ships its own code. Two products, one engine, one team.

Founders

James Kurrle

Founder and CEO

Critical-care physician with ten years of clinical and hospital leadership experience, dual-trained across Montréal and Sydney. Authors the clinical pathway engine and leads company strategy.

Read full bio

Vasken Dermardiros

Co-founder and CTO

PhD from Concordia University in building-energy machine learning. Owns hosting, AI inference, EMR integration, and the pathway authoring infrastructure that underpins both products.

Operating team

Who ships the work.

Josh Casey

Compliance and Cybersecurity

Owns the SOC 2 readiness programme, privacy impact assessments, cybersecurity posture, and regulatory-classification review for the clinic pathway library.

Shannon Kurrle

Resident Director, Aescia Pty Ltd

Resident Director of the Australian entity. ASIC-compliant governance role anchoring Aescia's Sydney operations.

Clinical collaborators

Named, attached to specific programmes.

Clinical leadership is attached to the programmes where the person actually does the work. Advisors are added here as each of them formally joins and consents to public acknowledgement.

Dr Kei Woldendorp

Clinical Advisor; Principal Investigator, SAFE-Discharge

BMed MBBS MPhil. Cardiothoracic researcher, The Baird Institute and Royal Prince Alfred Hospital. Principal Investigator of the SAFE-Discharge trial and Clinical Advisor to Aescia for Hospitals.

Clinical advisory

Formalising alongside the trial.

We do not publish advisory rosters we cannot stand behind. A clinical advisory is being formalised alongside the SAFE-Discharge trial at Royal Prince Alfred Hospital and the Product-Market-Fit programme at the CHEO Research Institute. Members are named here as each of them formally joins and consents to public acknowledgement.

For enquiries about the clinical advisory, use the contact page and we will route accordingly.

Want to meet the team?

Request a briefing